Overview
Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2022-12-01
2022-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate InjectionPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Sherief Abd-ElsalamTreatments:
Ethanolamine oleate
Criteria
Inclusion Criteria:- cirrhotic patients presented with actively bleeding
Exclusion Criteria:
- other sources of UGIB than esophageal varices, hepatic encephalopathy or
hepatocellular carcinoma (HCC)